GH Research PLC Ordinary Shares (GHRS) is a publicly traded Healthcare sector company. As of May 21, 2026, GHRS trades at $22.11 with a market cap of $1.49B and a P/E ratio of 0.00. GHRS moved +3.05% today. Year to date, GHRS is +45.80%; over the trailing twelve months it is +81.04%. Its 52-week range spans $6.00 to $24.66. Analyst consensus is strong buy with an average price target of $40.13. Rallies surfaces GHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Organigram’s Q2 Revenue Drops 9% with $5.8M Hemp Impairment; Sanity Deal to Add €25M: Organigram posted Q2 gross revenue of $93.3 million and net revenue of $59.8 million, down 9% year-over-year, and a net loss of $921,000 including a $5.8 million hemp impairment. Sanity acquisition is forecast to add €25 million quarterly revenue, while Moncton’s 32,000-kilogram harvest, up 56% YoY, awaits EU-GMP certification.
| Metric | Value |
|---|---|
| Price | $22.11 |
| Market Cap | $1.49B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.66 |
| 52-Week Low | $6.00 |
| Volume | 94 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
9 analysts cover GHRS: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $40.13.